QUINCE THERAPEUTICS INC (QNCX) Stock News

USA - NASDAQ:QNCX - US22053A1079 - Common Stock

1.645 USD

+0.01 (+0.3%)

Last: 10/3/2025, 11:28:36 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

QNCX Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

22 days ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

a month ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

2 months ago - By: Quince Therapeutics, Inc. - Mentions: OPCH

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

2 months ago - By: Benzinga - Mentions: LION APA MBX QBTS

This Lionsgate Studios Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

3 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

3 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

3 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference

4 months ago - By: Benzinga - Mentions: LIXT ATRA PPBT MODV ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

4 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

4 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

4 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

5 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

5 months ago - By: Yahoo Finance - Mentions: SRPT PLTR FTNT JPM

Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks

5 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Present at Citizens Life Sciences Conference

6 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

6 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

8 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

8 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

8 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

8 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

8 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

8 months ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

a year ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

a year ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

a year ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

a year ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Participate at Upcoming Investor Conferences

a year ago - By: Quince Therapeutics, Inc.

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: Quince Therapeutics, Inc.

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)